REPERFUSE研究协议:血管压缩剂治疗对败血症患者的 perfusion 的影响 - 一个机理性集中的随机对照试验
Rory McDonald1,2,3, James Watchorn2, Reena Mehta3,4,5
1Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
PloS one
|June 13, 2024
概括
这项研究调查了血管压素和血管素II如何影响败血症患者的 perfusion. 了解这些对脏微循环的影响是改善急性损伤 (AKI) 结果的关键.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症引起的急性损伤 (AKI) 是一种具有高死亡率的严重疾病.
- 患有严重AKI的败血性休克患者表现出皮层输液减少,尽管宏血管流量正常.
- 调查内 perfusion 异常可能会揭示感染性 AKI 的治疗点.
研究的目的:
- 为了检查血管压素和血管素II对败血症中脏微循环 perfusion 的影响.
- 阐明血管压缩剂治疗, perfusion 和 AKI 发展之间的关系.
- 通过使用先进的成像和监测技术,增强对败血症中 perfusion 动态的理解.
主要方法:
- 这是一项随机对照研究,涉及45名败血症休克患者.
- 被分配给静脉压素,血管增生素II或标准的上腺素治疗的患者.
- 通过对比增强超声波 (CEUS) 和尿液氧张力 (pO2) 评估的皮/脑髓输液; 通过超声波和心声学评估的宏血管流量; 通过暗场显微镜评估的微血管流量.
主要成果:
- 数据收集包括输液后的基线,1小时和24小时测量.
- 将监测全身和脏血流参数.
- 收集血液和尿液样本进行进一步分析.
结论:
- 血管压缩剂对于治疗败血症冲击至关重要.
- 这项研究旨在澄清特定血管压缩剂在 perfusion 和 AKI 中的作用.
- 这些发现将有助于全面了解性休克时的血液动力学.
更多相关视频
08:12Normothermic Ex Vivo Kidney Perfusion for the Preservation of Kidney Grafts prior to Transplantation
Published on: July 15, 2015
19.1K
07:03Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
Published on: February 15, 2022
1.4K
相关概念视频
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:23Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336